Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial.

Jackson RK, Liebich M, Berry P, Errington J, Liu J, Parker C, Moppett J, Samarasinghe S, Hough R, Rowntree C, Goulden NJ, Vora A, Kearns PR, Saha V, Hempel G, Irving JAE, Veal GJ.

Eur J Cancer. 2019 Sep 6;120:75-85. doi: 10.1016/j.ejca.2019.07.026. [Epub ahead of print]

PMID:
31499383
2.

In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis.

Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A, Berry P, Möcklinghoff T, Webber HT, Danielson LS, Buttery B, Calton EA, da Costa BM, Poon E, Jamin Y, Lise S, Veal GJ, Sebire N, Robinson SP, Anderson J, Chesler L.

Cancer Res. 2019 Aug 12. pii: canres.2759.2019. doi: 10.1158/0008-5472.CAN-18-2759. [Epub ahead of print]

PMID:
31405846
3.

The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression.

Hawley J, Veal GJ, Errington J, McDonald LG, Tweddle DA.

Pediatr Blood Cancer. 2019 Sep;66(9):e27825. doi: 10.1002/pbc.27825. Epub 2019 May 28.

PMID:
31135092
4.

Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste.

Smith SJ, Tyler BM, Gould T, Veal GJ, Gorelick N, Rowlinson J, Serra R, Ritchie A, Berry P, Otto A, Choi J, Skuli N, Estevez-Cebrero M, Shakesheff KM, Brem H, Grundy RG, Rahman R.

Clin Cancer Res. 2019 Aug 15;25(16):5094-5106. doi: 10.1158/1078-0432.CCR-18-3850. Epub 2019 May 21.

PMID:
31113843
5.

The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.

Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Osborne C, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O.

Cancer Cell. 2019 Apr 15;35(4):705. doi: 10.1016/j.ccell.2019.03.012. No abstract available.

6.

A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells.

Uitrakul S, Hutton C, Veal GJ, Jamieson D.

Eur J Clin Invest. 2019 Jul;49(7):e13115. doi: 10.1111/eci.13115. Epub 2019 Apr 8.

PMID:
30929275
7.

Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.

Veal GJ, Amankwatia EB, Paludetto MN, Möcklinghoff T, Thomson F, André N, Ciccolini J, Chatelut E.

Ther Drug Monit. 2019 Apr;41(2):142-159. doi: 10.1097/FTD.0000000000000606. Review.

PMID:
30883508
8.

Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.

Adamson PC, Veal GJ, Womer RB, Meany HJ, Bernhardt MB, Frazier AL, Balis FM.

Pediatr Blood Cancer. 2019 Jun;66(6):e27672. doi: 10.1002/pbc.27672. Epub 2019 Feb 15.

PMID:
30767382
9.

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.

Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA.

Int J Cancer. 2019 Jun 15;144(12):3146-3159. doi: 10.1002/ijc.32058. Epub 2019 Jan 9.

10.

The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.

Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Osborne C, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O.

Cancer Cell. 2018 Oct 8;34(4):626-642.e8. doi: 10.1016/j.ccell.2018.08.015. Erratum in: Cancer Cell. 2019 Apr 15;35(4):705.

11.

Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.

Duong JK, Veal GJ, Nath CE, Shaw PJ, Errington J, Ladenstein R, Boddy AV.

Br J Clin Pharmacol. 2019 Jan;85(1):136-146. doi: 10.1111/bcp.13774. Epub 2018 Nov 4.

PMID:
30261554
12.

The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.

Kim HY, Veal GJ, Zhou F, Boddy AV.

Eur J Clin Pharmacol. 2018 Dec;74(12):1575-1584. doi: 10.1007/s00228-018-2544-z. Epub 2018 Aug 30.

PMID:
30167756
13.

Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.

Fischer-Huchzermeyer S, Chikobava L, Stahn V, Zangarini M, Berry P, Veal GJ, Senner V, Mautner VF, Harder A.

BMC Res Notes. 2018 Jul 28;11(1):520. doi: 10.1186/s13104-018-3630-0.

14.

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.

Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA.

N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109.

15.

Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

Thomas F, Veal GJ, El Balkhi S, Lafont T, Picard N, Brugières L, Chatelut E, Piguet C.

Cancer Chemother Pharmacol. 2018 Aug;82(2):361-365. doi: 10.1007/s00280-018-3625-5. Epub 2018 Jun 19.

PMID:
29922990
16.

Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey.

Veal GJ, Malik S, Lupo M, MacFarlane S, Lepola P, Costello M, Ceci A, Boué C, Lecour C, Otto A, Rastegari M, Berry P.

BMJ Paediatr Open. 2017 Sep 5;1(1):e000170. doi: 10.1136/bmjpo-2017-000170. eCollection 2017.

17.

Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.

White-Koning M, Osborne C, Paci A, Boddy AV, Chatelut E, Veal GJ.

Eur J Cancer. 2018 Mar;91:56-67. doi: 10.1016/j.ejca.2017.11.029. Epub 2018 Jan 12.

18.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S.

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

19.

Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.

Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ.

Bioanalysis. 2017 Jul;9(13):1001-1010. doi: 10.4155/bio-2017-0043. Epub 2017 Jul 10.

PMID:
28692309
20.

Development and validation of LC-MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors.

Zangarini M, Rajan N, Danilenko M, Berry P, Traversa S, Veal GJ.

Bioanalysis. 2017 Feb;9(3):279-288. doi: 10.4155/bio-2016-0199. Epub 2017 Jan 23.

21.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26351. Epub 2016 Dec 1.

PMID:
27905678
22.

Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK.

Errington J, Malik G, Evans J, Baston J, Parry A, Price L, Johnstone H, Peters S, Oram V, Howe K, Whiteley E, Tunnacliffe J, Veal GJ.

Pediatr Blood Cancer. 2016 Jul;63(7):1193-7. doi: 10.1002/pbc.25960. Epub 2016 Mar 1.

23.

Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.

Veal GJ, Errington J, Sastry J, Chisholm J, Brock P, Morgenstern D, Pritchard-Jones K, Chowdhury T.

Cancer Chemother Pharmacol. 2016 Apr;77(4):685-92. doi: 10.1007/s00280-016-2975-0. Epub 2016 Feb 13.

24.

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN.

MAbs. 2016;8(3):604-16. doi: 10.1080/19420862.2015.1130196. Epub 2016 Jan 19.

25.

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.

Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV.

Eur J Cancer. 2016 Mar;55:56-64. doi: 10.1016/j.ejca.2015.12.007. Epub 2016 Jan 12.

26.

Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.

Jackson RK, Irving JA, Veal GJ.

Br J Haematol. 2016 Apr;173(1):13-24. doi: 10.1111/bjh.13924. Epub 2016 Jan 5. Review.

PMID:
26729065
27.

Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.

Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, Boddy AV, Veal GJ.

Br J Clin Pharmacol. 2016 May;81(5):989-98. doi: 10.1111/bcp.12878. Epub 2016 Feb 25.

28.

Carboplatin therapeutic monitoring in preterm and full-term neonates.

Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, Tweddle DA, Jenkinson H, Picton S.

Eur J Cancer. 2015 Sep;51(14):2022-30. doi: 10.1016/j.ejca.2015.07.011. Epub 2015 Jul 29.

29.

Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.

Avan A, Adema AD, Hoebe EK, Huijts CM, Avan A, Veal GJ, Ruijtenbeek R, Wosikowski K, Peters GJ.

Curr Drug Targets. 2014;15(14):1312-21.

PMID:
25382189
30.

Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.

Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ.

Clin Pharmacokinet. 2014 Aug;53(8):741-51. doi: 10.1007/s40262-014-0153-2.

31.

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson AD, Boddy AV.

Clin Cancer Res. 2013 Jan 15;19(2):469-79. doi: 10.1158/1078-0432.CCR-12-2225. Epub 2012 Oct 19.

32.

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Hill CR, Jamieson D, Thomas HD, Brown CD, Boddy AV, Veal GJ.

Biochem Pharmacol. 2013 Jan 1;85(1):29-37. doi: 10.1016/j.bcp.2012.10.004. Epub 2012 Oct 11.

33.

Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.

Gomaa MS, Lim AS, Lau SC, Watts AM, Illingworth NA, Bridgens CE, Veal GJ, Redfern CP, Brancale A, Armstrong JL, Simons C.

Bioorg Med Chem. 2012 Oct 15;20(20):6080-8. doi: 10.1016/j.bmc.2012.08.044. Epub 2012 Aug 30.

PMID:
22989911
34.

Institutional profile: pharmacogenomics research at Newcastle University.

Daly AK, Veal GJ, Jamieson D, Coulthard S.

Pharmacogenomics. 2012 Sep;13(12):1333-8. doi: 10.2217/pgs.12.123. No abstract available.

PMID:
22966883
35.

Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring.

Veal GJ, Boddy AV.

J Clin Oncol. 2012 Sep 20;30(27):3424; author reply 3425. doi: 10.1200/JCO.2012.43.5677. Epub 2012 Jul 30. No abstract available.

PMID:
22851560
36.

Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.

Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein R, Vassal G.

Eur J Cancer. 2012 Nov;48(16):3063-72. doi: 10.1016/j.ejca.2012.05.020. Epub 2012 Jun 26.

PMID:
22742881
37.

Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.

Gomaa MS, Bridgens CE, Illingworth NA, Veal GJ, Redfern CP, Brancale A, Armstrong JL, Simons C.

Bioorg Med Chem. 2012 Jul 15;20(14):4201-7. doi: 10.1016/j.bmc.2012.05.076. Epub 2012 Jun 7.

PMID:
22727372
38.

Chemotherapy in newborns and preterm babies.

Veal GJ, Boddy AV.

Semin Fetal Neonatal Med. 2012 Aug;17(4):243-248. doi: 10.1016/j.siny.2012.03.002. Epub 2012 Mar 28. Review.

PMID:
22464845
39.

Novel micelles based on amphiphilic branched PEG as carriers for fenretinide.

Orienti I, Zuccari G, Falconi M, Teti G, Illingworth NA, Veal GJ.

Nanomedicine. 2012 Aug;8(6):880-90. doi: 10.1016/j.nano.2011.10.008. Epub 2011 Nov 15.

PMID:
22094120
40.

Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.

Jarvis IW, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ.

Biochem Pharmacol. 2012 Jan 1;83(1):69-77. doi: 10.1016/j.bcp.2011.10.005. Epub 2011 Oct 14.

PMID:
22015635
41.

The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide.

Armstrong JL, Martin S, Illingworth NA, Jamieson D, Neilson A, Lovat PE, Redfern CP, Veal GJ.

Oncol Rep. 2012 Jan;27(1):293-8. doi: 10.3892/or.2011.1479. Epub 2011 Sep 29.

PMID:
21964808
42.

Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).

Gomaa MS, Bridgens CE, Veal GJ, Redfern CP, Brancale A, Armstrong JL, Simons C.

J Med Chem. 2011 Oct 13;54(19):6803-11. doi: 10.1021/jm200695m. Epub 2011 Sep 8.

PMID:
21838328
43.

Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M.

Eur J Cancer. 2011 Jul;47(10):1556-63. doi: 10.1016/j.ejca.2011.03.008. Epub 2011 Apr 7.

PMID:
21482104
44.

Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.

Gomaa MS, Bridgens CE, Aboraia AS, Veal GJ, Redfern CP, Brancale A, Armstrong JL, Simons C.

J Med Chem. 2011 Apr 28;54(8):2778-91. doi: 10.1021/jm101583w. Epub 2011 Mar 23.

PMID:
21428449
45.

Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.

Illingworth NA, Boddy AV, Daly AK, Veal GJ.

Br J Pharmacol. 2011 Feb;162(4):989-99. doi: 10.1111/j.1476-5381.2010.01104.x.

46.

Oxazaphosphorines: new therapeutic strategies for an old class of drugs.

Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):919-38. doi: 10.1517/17425255.2010.487861. Review.

PMID:
20446865
47.

Clinical pharmacology in the adolescent oncology patient.

Veal GJ, Hartford CM, Stewart CF.

J Clin Oncol. 2010 Nov 10;28(32):4790-9. doi: 10.1200/JCO.2010.28.3473. Epub 2010 May 3. Review.

48.

Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.

Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK.

Drug Metab Dispos. 2010 Aug;38(8):1261-6. doi: 10.1124/dmd.109.030866. Epub 2010 Apr 26.

PMID:
20421446
49.

Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate.

Israels T, Damen CW, Cole M, van Geloven N, Boddy AV, Caron HN, Beijnen JH, Molyneux EM, Veal GJ.

Eur J Cancer. 2010 Jul;46(10):1841-7. doi: 10.1016/j.ejca.2010.03.002. Epub 2010 Apr 9.

PMID:
20382523
50.

Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.

Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV.

Drug Metab Dispos. 2010 Jul;38(7):1211-7. doi: 10.1124/dmd.109.031625. Epub 2010 Mar 22.

PMID:
20308471

Supplemental Content

Support Center